Data alert

The INTERHEART Study: New data on global risk

Cardiovascular disease (CVD) is estimated to be the leading cause of mortality and morbidity worldwide. While age-adjusted death rates from CVD have fallen in developed countries, CVD rates have risen dramatically in other parts of the world. However, our understanding of prevention of CVD and coronary heart disease (CHD) has been based mainly on studies of patients of European origin.1,2

Major risk factors contributing to the global burden of CHD include hypercholesterolemia (56%), hypertension (49%), low fruit and vegetable intake (31%), lack of physical activity (22%), overweight (21%), and tobacco use (12%). These risk factors account for more than 80% of CHD mortality and morbidity worldwide and 12.6% of the total global disease burden.3

INTERHEART is a large, international, case-control study designed to determine the importance of risk and protective factors for CHD worldwide.4,5 The investigators examined whether the association of any of these CV risk or protective factors varied by geographic region, or with ethnicity, age, or gender. INTERHEART found that regardless of age, gender, or ethnicity, a set of nine CV risk factors accounts for 90% of the risk of first acute myocardial infarction (MI) globally.

References are listed at the end of the Data Alert.

INTERHEART: Focus on 9 risk or protective factors

Download 04DA_INTERHEART.ppt (7 slides - 0.2MB)

INTERHEART: Focus on 9 risk or protective factors INTERHEART: ApoB-ApoA1 ratio—Graded relation to MI risk, no evidence for a threshold INTERHEART: Significant association of MI
risk with hypertension INTERHEART: Impact of multiple risk factorson CV risk INTERHEART: Association of risk factorswith acute MI in women and men Adherence to simultaneous antihypertensive and lipid-regulating drug therapy INTERHEART: Clinical implications
Data_Alert.pdf (0.8MB)Data_Alert.pdf (0.8MB)


Related at vwbg.org

The new mandate for multiple risk reduction

Reducing the morbidity and mortality associated with cardiovascular (CV) disease is becoming as much a public health challenge as it is a research challenge.

Blunting the atherosclerotic process in patients with coronary artery disease

Statin therapy lowers serum levels of atherogenic lipoproteins and reduces cardiovascular (CV) morbidity and mortality in a wide range of patients in clinical trials.

Core Curriculum

Leading the Way in Cardiovascular Regenerative Medicine

View/Download individual slides (54 Slides)
More related